Legislation & Regulation

In a January 15th letter to President-elect Joseph R. Biden, AMCP shared its priority issues related to the COVID-19 pandemic and managed care pharmacy.

Partnership Forum: The market for biologic drugs in the United States is large and has the potential to play an increasingly important role in the country’s health care system — both in the treatment of disease and in the affordability of drugs. Biosimilar approval and marketing of products in the United States is at a slower pace than desired by many stakeholders. This forum helped identify key actions that could support the further development and use of biologics in the U.S. health care system.

Sponsored webinar that highlighted a new frontier of cannabis-related advocacy—state mandated health insurance coverage for non-FDA-approved cannabis products.

Sponsored webinar that highlighted a new frontier of cannabis-related advocacy—state mandated health insurance coverage for non-FDA-approved cannabis products.

Information from state governments regarding COVID-19.

The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare & Medicaid Services (CMS) for the opportunity to provide comments in response to its proposed rule, “Medicare and Medicaid Programs; Contract Year 2021 and 2022 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicaid Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly” published on February 18, 2020.

AMCP webinar that reviewed the provisions contained in the proposed Contract Year 2021 and 2022 Medicare Advantage and Part D rule that was released by the Centers for Medicare and Medicaid Services (CMS) on February 5, 2020.

AMCP webinar that reviewed the provisions contained in the proposed Contract Year 2021 and 2022 Medicare Advantage and Part D rule that was released by the Centers for Medicare and Medicaid Services (CMS) on February 5, 2020.

On February 5, 2020, the Centers for Medicare & Medicaid Services (CMS) released the CY 2021 and 2022 Medicare Advantage and Medicare Prescription Drug Benefit Program Policy and Technical Rule, outlining proposed programmatic changes to the MA and Part D programs for two upcoming contract years. In a break from historic precedent, many of the program and policy changes that historically had been included in the Draft Call Letter were included in this proposed rule.

AMCP announced today that Phil Bongiorno has joined the organization as vice president, policy & government relations. In this role, he will oversee AMCP’s many advocacy efforts to advance managed care pharmacy principles and practices through health care legislation and regulation at both the federal and state levels.

Press Release: AMCP comments in joint statement on the Administration’s latest initiative to modernize substance use disorder (SUD) treatment privacy law and enhance coordinated care and safety.